Acetyl-CoA-producing enzymes are a targetable metabolic entry point to MASLD and liver fibrosis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41500201.
- Also identified by DOI 10.1016/j.cmet.2025.12.005.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lipogenesis is one of the main drivers of metabolic dysfunction-associated steatotic liver disease (MASLD). The previewed work decreased acetyl-CoA by inhibiting ATP citrate lyase (ACLY) and acyl-CoA synthetase short-chain family member 2 (ACSS2) via EVT0185, thus inhibiting lipogenesis, hepatocyte metabolic stress, and hepatic stellate cell activation, reducing liver fibrosis.
Medical subject headings
- Liver Cirrhosis
- Acetyl Coenzyme A
- ATP Citrate (pro-S)-Lyase
- Fatty Liver